전이성 폐선암 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Metastatic Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,221,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,602,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,366,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

전이성 폐선암 치료 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 전 세계 전이성 폐선암 치료 시장 규모는 2030년까지 92억 9,000만 달러에 달할 것이며, 2025-2030년 11.3%의 CAGR로 확대될 것으로 추정됩니다.

이러한 확대에는 유병률의 증가, 치료 기술의 발전, 규제 및 정부 지원책 등 몇 가지 중요한 요인이 있습니다. 세계보건기구(WHO)에 따르면, 폐암은 여전히 전 세계적으로 가장 많이 진단되는 암으로 매년 약 250만 명이 새로 발병하며, 전체 신규 암 환자의 12.4%를 차지합니다. 이러한 높은 발병률은 효과적인 치료법에 대한 시급한 수요를 강조하고 있습니다.

최근 치료 동향은 시장 개척에 크게 기여하고 있으며, ALK 억제제 및 EGFR 억제제를 포함한 표적 치료와 같은 혁신은 전이성 폐선암 관리에 혁명을 일으켰습니다. 예를 들어, 2024년 3월 화이자(Pfizer)는 3상 CROWN 검사의 장기 추적 데이터를 발표했습니다. 이 시험은 ALK 양성 진행성 비소세포폐암(NSCLC) 환자를 대상으로 3세대 ALK 억제제인 로브레나(LORBRENA)의 효능을 XALKORI와 비교하여 평가한 것입니다. 로브레나(로라티닙)와 타그리소(오시머티닙)와 같은 약제는 환자들에게 새로운 희망을 주며 생존율과 삶의 질 개선으로 이어지고 있습니다. 또한, 체크포인트 억제제와 같은 면역요법의 도입이 증가하면서 치료 옵션은 더욱 다양해지고 있습니다.

규제 기관은 시장 성장을 촉진하는 데 있어 중요한 역할을 하고 있습니다. 미국 식품의약국(FDA)과 유럽의약품청(EMA)과 같은 기관은 유망한 치료법에 대한 신속한 승인 절차를 도입하여 새로운 치료법에 대한 환자의 접근성을 높이고 있습니다. 또한, 미국의 National Cancer Moonshot Initiative, 유럽연합(EU)의 Horizon Europe 프로그램과 같은 정부 이니셔티브는 연구 자금을 지원하고 새로운 치료법 개발을 지원하여 전이성 폐선암의 시장 확대와 치료 옵션 개발에 기여하고 있습니다.

전이성 폐선암 치료 시장 보고서 하이라이트

• 치료법에 따라 시장은 화학요법, 표적치료, 면역요법, 방사선치료, 기타로 분류되며, 2024년 화학요법 부문은 전이성 폐선암 치료 시장에서 36%의 가장 큰 매출 점유율을 차지했습니다.
• 병원 부문은 2024년 63.9%의 가장 큰 수익 점유율을 차지했습니다. 병원은 일반적으로 첨단 진단 및 치료 시설을 갖추고 있어 복잡한 암 치료에 적합한 환경을 갖추고 있습니다.
• 북미 전이성 폐선암 치료 시장은 높은 질병 유병률과 기술 혁신에 대한 관심에 힘입어 성장하고 있습니다. 폐암, 특히 선암의 발병률이 증가함에 따라 종양의 유전자 프로파일에 따라 보다 맞춤화된 치료 전략이 채택되고 있습니다.
• 표적 치료제 부문은 암의 특정 분자 동인을 정확하게 표적화할 수 있는 능력으로 인해 2025-2030년 사이 12.9%의 CAGR을 기록하며 가장 빠르게 성장하는 부문으로 부상할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 전이성 폐선암 치료 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석

제4장 전이성 폐선암 치료 시장 : 치료 비즈니스 분석

• 치료 시장 점유율, 2024년과 2030년
• 치료 부문 대시보드
• 시장 규모와 예측과 동향 분석, 치료별, 2018-2030년
• 화학요법
• 표적요법
• 면역요법
• 방사선 치료
• 기타

제5장 전이성 폐선암 치료 시장 : 최종 용도 비즈니스 분석

• 최종 용도 시장 점유율, 2024년과 2030년
• 최종 용도 부문 대시보드
• 시장 규모와 예측과 동향 분석, 최종 용도별, 2018-2030년
• 병원
• 전문 클리닉
• 기타

제6장 전이성 폐선암 치료 시장 : 지역별, 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 스페인
  • 이탈리아
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 참여자 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • Pfizer Inc.
  • Eli Lilly and Company
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Merck KGaA(EMD Serono)
  • F. Hoffmann-La Roche Ltd
  • GSK plc.
  • AbbVie Inc.

ksm

영문 목차

영문목차

Metastatic Lung Adenocarcinoma Treatment Market Growth & Trends:

The global metastatic lung adenocarcinoma treatment market size is estimated to reach USD 9.29 billion by 2030, expanding at a CAGR of 11.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This expansion is fueled by several key factors, including the rising prevalence of the disease, advancements in treatment technologies, and supportive regulatory and government initiatives. According to the World Health Organization (WHO), lung cancer remains the most diagnosed cancer globally, with approximately 2.5 million new cases each year, representing 12.4% of all new cancer cases. This high incidence rate underscores the urgent demand for effective treatment solutions.

Recent developments in treatment have significantly contributed to market growth. Innovations such as targeted therapies, including ALK inhibitors and EGFR inhibitors, have revolutionized the management of metastatic lung adenocarcinoma. For instance, in March 2024, Pfizer Inc. published long-term follow-up data from the Phase 3 CROWN trial. This study assessed the effectiveness of LORBRENA, a third-generation ALK inhibitor, in comparison to XALKORI for patients with newly diagnosed, ALK-positive advanced non-small cell lung cancer (NSCLC). Drugs such as LORBRENA (lorlatinib) and TAGRISSO (osimertinib) offer new hope for patients, leading to improved survival rates and quality of life. Moreover, the increasing adoption of immunotherapies, such as checkpoint inhibitors, has further expanded treatment options.

Regulatory bodies play a crucial role in facilitating market growth. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have implemented expedited approval processes for promising therapies, accelerating patient access to new treatments. Additionally, government initiatives, such as the National Cancer Moonshot Initiative in the U.S. and the European Union's Horizon Europe program, are funding research and supporting the development of novel therapies, contributing to the market's expansion and the advancement of treatment options for metastatic lung adenocarcinoma.

Metastatic Lung Adenocarcinoma Treatment Market Report Highlights:

• Based on treatment, the market is segmented into chemotherapy, targeted therapy, immunotherapy, radiation therapy and others. In 2024, the chemotherapy segment accounted for the largest revenue share of 36% in metastatic lung adenocarcinoma treatment market
• The hospital segment accounts for the largest revenue share of 63.9% in 2024. Hospitals are typically equipped with advanced diagnostic and treatment facilities, making them the preferred setting for complex cancer care
• The North American metastatic lung adenocarcinoma treatment market is driven by high disease prevalence and a strong emphasis on innovation. The rising incidence of lung cancer, particularly adenocarcinoma, has led to the adoption of more personalized treatment strategies tailored to the genetic profiles of tumors
• The targeted therapy segment is anticipated to emerge as the fastest-growing segment and register a CAGR of 12.9% from 2025 to 2030, owing to its ability to target specific molecular drivers of cancer precisely.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Metastatic Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis

Chapter 4. Metastatic Lung Adenocarcinoma Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2030
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, By Treatment, 2018 to 2030 (USD Million)
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
• 4.6. Immunotherapy
  • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
• 4.7. Radiation Therapy
  • 4.7.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
• 4.8. Other
  • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Metastatic Lung Adenocarcinoma Treatment Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, By End Use, 2018 to 2030 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Metastatic Lung Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamic
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamic
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamic
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamic
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamic
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamic
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamic
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Spain Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Italy
    • 6.5.6.1. Key Country Dynamic
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Italy Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamic
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamic
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Norway Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamic
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamic
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamic
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamic
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamic
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamic
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamic
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamic
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamic
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamic
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamic
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamic
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamic
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Metastatic Lung Adenocarcinoma Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Pfizer Inc.
    • 7.5.1.1. Participant's Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Eli Lilly and Company
    • 7.5.2.1. Participant's Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. AstraZeneca
    • 7.5.3.1. Participant's Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Bristol-Myers Squibb Company
    • 7.5.4.1. Participant's overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Boehringer Ingelheim International GmbH
    • 7.5.5.1. Participant's Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Novartis AG
    • 7.5.6.1. Participant's Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Merck KGaA (EMD Serono)
    • 7.5.7.1. Participant's Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. F. Hoffmann-La Roche Ltd
    • 7.5.8.1. Participant's Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. GSK plc.
    • 7.5.9.1. Participant's Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. AbbVie Inc.
    • 7.5.10.1. Participant's Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

관련자료